United States


BAYZF.PK on OTC Markets Group

11:19am EDT
Change (% chg)

$2.21 (+2.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BAYZF.PK


Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic... (more)


Beta: 0.91
Market Cap(Mil.): €73,019.49
Shares Outstanding(Mil.): 826.95
Dividend: 2.50
Yield (%): 2.83


  BAYZF.PK Industry Sector
P/E (TTM): 16.67 36.90 36.83
EPS (TTM): 5.30 -- --
ROI: 8.03 14.48 13.93
ROE: 19.44 15.27 14.84

BRIEF-Bayer and DelSiTech partner to develop drug delivery technology for Ophthalmology

* Delsitech to receive number of undisclosed milestone payments triggered by successful completion of different stages of development

Sep 29 2016

Monsanto ally Novozymes sees opportunity, risk in Bayer merger

LONDON Novozymes , already grappling with the consequences of low oil and crop prices, is watching anxiously to see what Bayer's purchase of Monsanto will mean for the Danish group's ties with its key agricultural partner.

Sep 28 2016

BRIEF-Bayer To start phase III study with Vericiguat

* Says first patient was enrolled in Victoria, a pivotal phase III clinical study led by Bayer's collaboration partner msd

Sep 28 2016

BRIEF-Monsanto India says board to consider Bayer's open offer on Sept 26

* Meeting on Sept 26 to consider announcement made by Bayer on September 19 regarding open offer Further company coverage:

Sep 22 2016

BRIEF-Monsanto Co - Bayer is committed to make divestitures to obtain antitrust approvals

* Bayer is committed to make divestitures if required up to $1.6 billion to obtain antitrust approvals for merger

Sep 21 2016

BRIEF-Evotec, Bayer to develop new treatments to fight kidney diseases

* Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients

Sep 21 2016

BRIEF-Monsanto Co - Bayer not required to take any material adverse divestiture action

* Bayer not required to take any divestiture action that would likely result in 1-year loss of net sales to Bayer, co in excess of $1.6 billion

Sep 20 2016

BRIEF-Monsanto India says Bayer announces open offer to acquire 26 pct in co

* Bayer announces open offer to acquire 26 percent in co Source text: (http://bit.ly/2cMLWIh)

Sep 20 2016

Bayer raises sales targets for top-selling drugs after Monsanto deal

FRANKFURT German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

Sep 20 2016

UPDATE 1-Bayer raises sales targets for top-selling drugs after Monsanto deal

* Bayer shares seen 1.5 pct higher (Adds consumer care unit target, analyst comment, premarket share price)

Sep 20 2016

Earnings vs. Estimates